IDT Biologika is a global biopharmaceutical contract development and manufacturing organization (CDMO) that specializes in the production of innovative live viral vaccines, viral vectors for gene and immune therapeutics as well as fill/finish of sterile liquid and lyophilized biologics to improve human health worldwide.

We offer clients in B2B business a single source CDMO partner at our sites in Germany and the USA, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. This includes process development, drug substance manufacture, drug product manufacture, packaging, quality control/analytics and storage. IDT Biologika handles every step in manufacturing and packaging of small clinical batches as well as of products in a large-scale commercial scale.

At its headquarters in Germany, IDT Biologika operates one of Europe’s premiere integrated facilities for end-to-end services from process development through clinical phases I-III to commercial manufacturing. In Rockville, MA, USA we utilize broad capabilities and a depth of technologies for process development and manufacturing of clinical trial material for phases I-II.

Our fully integrated services are underscored by our commitment to quality and operational excellence that flows through our best-in-class process and cGMP (up to BSL2) manufacturing capabilities meeting EMA and FDA standards (ANVISA ready).

Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as tuberculosis, AIDS, malaria, cancer, dengue and ebola.

Shortly after the outbreak of the corona epidemic IDT
Biologika started collaboration with the German Center for Infection Research
(DZIF), the universities in Munich and Marburg for the development of a SARS-CoV-2 vector vaccine.

On request of our clients we supply their products in vials, pre-filled syringes (with and without safety devices), autoinjectors or as combination products.

Panel: What’s our global pandemic preparedness response for Coronavirus?

Information

Session Type

Log in